

KATERINA M. ANTONIOU, MD, PhD

ERS Assembly 12 Head (2021-2024)

Professor of Respiratory Medicine, School of Medicine, University of Crete
Molecular & Cellular Pulmonology Laboratory, Dept. of Respiratory Medicine
Email: kantoniou@uoc.gr

Date of birth: 25.07.1972

Place of birth: Heraklion Crete

Medical specialties: Respiratory Medicine 2000-2005 (Boards 2005)

Academic Degrees:

- MD, Naples University, FEDERICO II, 1998
- PhD, Faculty of Medicine, University of Crete, 2004

Research interests: Interstitial Lung Diseases, Connective tissue Diseases, Pleural Diseases, Epigenetics & Genetics in Chronic Lung Diseases, Lung Cancer Pathogenesis, Severe Asthma, Bronchiectasis, Pulmonary Hypertension ILD

Supervisor in 18 PhD theses and 2 MSc thesis in the Faculty of Medicine, University of Crete

Editor: Guest editor, Frontiers in Immunology, Research Topic "Mechanisms of Lung Fibrosis: is Immunity Back in the Game?"

Associate Editor: ERR, Breath, Pulmonology.

Reviewer of Journals: Lancet, Lancet Respir Med, AJRCCM, BMJ, Eur. Respir Journal, Chest, Respir Res, Respir Med, Respiriology, Respiration, Pulmonary Pharmacology & Therapeutics, etc

Publications: 261 (Pub Med, ISI, Scopus)

Citations: 16.549 by Scopus, 20.135 by Researchgate (12/02/2026)

H-index: 64 by Scopus, 54 by Researchgate (12/02/2026)

Invited speaker in international congresses: >200

Chair in international meetings-congresses: >180

Principal Investigator in IPF clinical trials: 32, PI in Severe Asthma, Bronchiectasis

Member of ERS/ATS research statement: Interstitial pneumonia with autoimmune features (EurRespir J2015; 46:976-87)

Member of the Statement on Combined pulmonary fibrosis and emphysema (CPFE) (TF-2018-15)

Co-chair in CTD-ILD Guidelines (ERS-EULAR) "Clinical practice guideline on connective tissue diseases with interstitial lung (ILD) involvement" (TF-2020-03, EurRespir J, under revision)

Co-chair of ERS Statement on Covid-19 Follow-Up (TF-2020-14, EurRespir J 2022)

Member of ERS Guidelines for management of Covid-19 (EurRespir J 2021)

Member in ERS clinical practice guidelines on treatment of sarcoidosis (EurRespir J2021)

Member of PVRI Working group about PH-ILDs (2021-today)

Member of Idiopathic Pulmonary Fibrosis (IPF)-An update of diagnosis and treatment recommendations: Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines (TF-2019-18, EurRespir J 2022)

Member in "Update of the International Multidisciplinary Classification of the Interstitial Pneumonias: An ERS/ATS Statement", EurRespir J. (under submission)

Member of ERS Research Statement: diagnosis and management of post-COVID interstitial lung disease (ongoing, ERS TF-2022-09)

Posts:

- Honorary Research Fellow (ERS long term fellowship, Prof Wells, Royal Brompton Hospital, 2005-2006)
- Pre- Lecturer in the Department of Respiratory Medicine Faculty of Medicine, University of Crete (2006- 2009)
- Lecturer of Respiratory Medicine, Faculty of Medicine, University of Crete (2009- 2014)
- Assistant Professor of Respiratory Medicine, Faculty of Medicine, University of Crete (2014- 2018)
- Associate Professor of Respiratory Medicine, Faculty of Medicine, University of Crete (2018-2022)
- Professor of Respiratory Medicine, Faculty of Medicine, University of Crete (2022-today)
- Vice Dean, Faculty of Medicine (2015-2017)
- Coordinator of Public Relationship Committee (Rectorship, University of Crete) (2016-2017)
- Chair of the Committee of Protocol-Extroversion and Public Relations, Faculty of Medicine, University of Crete (2020-2022)
- Coordinator of ILD Working Group of the Hellenic Thoracic Society (2011-2017)
- ERS Interstitial Lung Diseases Group Secretary (2011-2014)

- ERS Interstitial Lung Diseases Group Chair (2014-2017)
- ERS Assembly 12 Secretary (2018-2021)
- ERS Assembly 12 Chair (2021- 2024)
- WASOG executivecommittee: (2021- today)
- Head of Laboratory of Molecular and Cellular Pulmonology, University of Crete (2014-today)
- Member of the Ethics Committee of the University General Hospital of Heraklion, Crete (2014-today)
- Alternate Member of the Board of the University General Hospital of Heraklion, Crete (2020-2021)
- Member of the Postgraduate Studies Committee, Faculty of Medicine, University of Crete (2014-2016)
- Faculty Member of the General Assembly, Faculty of Medicine, University of Crete (2009-2012), (2014-2016), (2019-2020), (2021-2022)
- Member of the ERS Evaluation Committee for Fellowships and Visiting Professorships, 2011-2017
- ERS Abstract Reviewer 2010- 2021
- Member of the ERS Evaluation Committee for Fellowships and Visiting Professorships, 2011-2017
- Member of the General Medical Council
- Member of ERS, ATS, HTS, WASOG

Organization of internationalconferences:

- Member of Organizing Committee of 9th WASOG Meeting & 11th BAL International Conference
- Pulmonary Review and Refreshing Course of Pulmonary Medicine in Interstitial Lung Diseases, 2009
- ERS Research Seminar on “Novel insights in pulmonary fibrogenesis” from bench to bedside 2010
- Scientific Committee of the Hellenic Thoracic Society Congress (21th) 2012
- National Congresses of the Hellenic Thoracic Society, Coordinator of the ILD Group 2012-2017
- IPF and Sleep: Common pathways and implications in therapy; Endorsed by the ERS 2013
- ERS Research Seminar on “IPF and Cancer: Wounds that do not heal” 2015
- Cretan Summer School of Respiratory Department (SHARE), Interstitial Lung diseases (ILDs) course: from bench to bedside 2017, University of Crete
- International WASOG conference (endorsed by ERS), Heraklion, 2018
- 1stILD Turkish Greek Workshop, Izmir, 2024
- 2nd ILD Turkish Greek Workshop, Heraklion, 2025

Research monograph:

1. Immunotherapy for pulmonary fibrosis: a light in the dark? EurRespir Top 2000
2. Do patients with cryptogenic fibrosing alveolitis have increased risk of Lung Cancer? EurRespir Top 2000
3. Transforming growth factor (TGF- β) induces pleurodesis significantly faster than talc. EurRespir Top 2001
4. Influence of diuretics on transudative pleural effusions. EurRespir Top 2002
5. Hot Topic. High-dose acetylcysteine in idiopathic pulmonary fibrosis. Breath, June 2006.
6. Diffuse parenchymal lung disease: a different perspective. Breathe 2008
7. Pleural Effusions in pregnancy and gynecological diseases. Pleural Diseases. Marcel Dekker
8. Pleural Effusions in pregnancy and gynecological diseases. Pleural Diseases. Marcel Dekker 2nd edition
9. Immunological Diseases of the Pleura. Pleural Effusions in pregnancy and gynecological diseases. Pleural Diseases. Marcel Dekker (2nd edition)
10. Interstitial lung disease in SSc. In Scleroderma-modern aspects of pathogenesis, diagnosis and therapy, by Oliver Distler
11. Immunopathogenesis of Sarcoidosis, Sarcoidosis Diagnosis and Management, ISBN 978-953-307-414-6
12. Chapter 25. Interstitial Lung Disease in Systemic Sclerosis. Orphan Lung Disease. Springer-Verlag London
13. Chapter 14. CPFE: distinctive and non-distinctive features. Idiopathic Pulmonary Fibrosis. ERS monograph. 2016.
14. Chapter 7. Pulmonary involvement inSystemic lupus erythmatosus, sjogren syndrome and mixed connective tissue disease. ERS Monograph.2019.
15. Systemic Sclerosis and the Lung. In: Cottin, V., Richeldi, L., Brown, K., McCormack, F.X. (eds) Orphan Lung Diseases.2023.
16. Systemic inflammatory diseases with lung involvement. In: Wagner TOF, Humbert M, Wijsenbeek M, et al., eds. Rare Diseases of the Respiratory System, ERS Monograph. 2023

Academy memberships:

- ERS Abstract Reviewer 2010- 2017
- Member of the ERS Evaluation Committee for Fellowships and Visiting Professorships, 2011-2017
- Reviewer in Lancet, BMJ, ERJ, Respiratory Medicine, Respiration, J Rheumatology, etc
- Member of the General Medical Council
- Member of “International Working Group on Undifferentiated forms of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)”, ATS/ERS Task Force
- Collaborative Project: Investigating the syndrome of Combined Pulmonary Fibrosis and Emphysema (CPFE)
- Member of ERS Task Force for IPF Diagnosis
- ERS Task Force for CTD-ILD
- ERS Sarcoidosis guidelines
- ERS Post COVID-19 guidelines

Prizes/ Awards:

- Short Term Research Fellowship, ERS, Imperial College Royal Brompton Hospital.
- Long Term Research Fellowship, ERS, Imperial College Royal Brompton Hospital.
- Alfred Soffer Research Award ACCP Annual Meeting, Orlando, Florida
- Idiopathic Pulmonary Fibrosis Research Award, ERS Vienna 2012, Supported by Intermune

Funded projects as Coordinator and Partner:

- (Ε.Π.Ε.Α.Ε.Κ. II) PYTHAGORAS II: Support grant at the universities (50.000 euros): 2005-2007(co-investigator)
- 9 Unrestricted grants by Hellenic Thoracic Society, Research Award (15.000 euros each) years 2008, 2009, 2010, 2012, 2013, 2016, 2017, 2018, 2022
- Idiopathic Pulmonary Fibrosis Research Award, ERS Vienna 2012, Supported by Intermune, (7.500Euros)
- Successful application for European Respiratory Society (ERS) Respire2 Respiratory Host Center (for post-doc fellowship position, 20000 euros/fellow–year)
- 7th Framework Program for Research, EU. Title: “Enhancing University of Crete Medical School Scientific Excellence and Translational Research Potential in Human Diseases”. (3,410,160 euros). January 2012-December 2014. (Co-investigator).
- 3 Unrestricted research grants by Hoffman La-Roche 2015, 2016, 2017, 2018.
- 4Unrestricted grants by Boehringer Ingelheim 2016, 2017,2018, 2020.
- Recipient of Hellenic Foundation for Research and Innovation HFRI grant for Faculty members (2020), “Metabolic FibroClock” (180,000 euros)

Organization of meetings-seminars:

- IPF and Sleep: Common pathways and implications in therapy; Endorsed by the ERS 2013
- Cretan Summer School of Respiratory Department (SHARE), Interstitial Lung diseases (ILDs) course: from bench to bedside 2017, University of Crete
- International WASOG conference (endorsed by ERS), Heraklion, 2018.
- 2nd Cretan Summer School of Respiratory Department SHARE, Heraklion 2022
- 3rd SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Heraklion 2023
- 4rd SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Heraklion 2024
- 5th SHARE CONGRESS Science in Heraklion Awareness in Respiratory and Sleep Evolution, Heraklion 2025

Principal and Sub/ Investigator in IPF clinical trials:

1. 1199.33 B.I: An open label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis.
2. MA29957 ROCHE: A Phase IIb Multicenter , Randomised , Double -Blind ,Placebo controlled Study to evaluate the efficacy ,safety ,and tolerability of Sildenafil added to Pirfenidone in patients with advanced idiopathic Pulmonary Fibrosis and intermediate or high probability of group 3 Pulmonary Hypertension.

3. ML39259 ROCHE: A Multicenter, Post Marketing, Non Interventional Observational Study to evaluate quality of life in patients in Greece with Idiopathic Fibrosis under treatment with pirfenidone– The Pneumon Study.
4. 1199.252 INDULGE IPF B.I: Investigating idiopathic pulmonary fibrosis in Greece (INDULGE IPF).
5. CC-90001-IPF_-001 . CELGENE: A Phase 2, 24-week, randomised, double-blind, placebo -controlled , multicenter study, followed by 28-week treatment extension , to evaluate the efficacy and safety of CC-90001 in subjects with Idiopathic Pulmonary Fibrosis.
6. MA39189 ROCHE: Multicenter, international, double-blind, two-arm, randomized, placebo-controlled phase ii trial of pirfenidone in patients with unclassifiable progressive fibrosing ILD.
7. DRI11772 SANOFI: Efficacy and safety of SAR156597 in the treatment of Idiopathic Pulmonary Fibrosis: A Randomised , double-blind , placebo controlled , 52-week dose-ranging study.
8. MA39293-DIET CIBER: An open label phase IV, multicenter, international, interventional study to evaluate the effect of diet on gastrointestinal adverse events in patients with IPF treated with Pirfenidone.
9. 203PF203 BIOGEN: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis.
10. 1199-0355 BOEHRINGER INGELHEIM: Investigating Trends in Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF) Under Treatment with Nintedanib.
11. GLPG1690-CL-303 GALAPAGOS: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.
12. 0352-2144 BOEHRINGER INGELHEIM: An interventional study without an investigational medicinal product to differentially diagnose patients with interstitial lung diseases (ILDs), to monitor disease progression, and to identify molecular markers.
13. RPL554-CO-301 VERONA PHARMA: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine over 24 Weeks (With a 48-Week Safety Subset) in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease.
14. WA42294 :A phase III open-label extension study to evaluate long-term safety and efficacy of prm-151 in patients with idiopathic pulmonary fibrosis (IPF)
15. WA 42293 : A phase III Randomised , Double –blind, Placebo –controlled , trial to evaluate the efficacy and safety of PRM -151 with patients with idiopathic pulmonary fibrosis (IPF)
16. EFC15808 (NOTUS): A Randomized , Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy Safety, and Tolerability of Dupilumab in Patients with Moderate –to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation.
17. HZNP-HZN-825-303: A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis.
18. LYT-100-2022-204: A randomized double-blind, four arm active and placebo-controlled dose-finding trial to evaluate the efficacy, tolerability, and safety dose response of LYT-100 in patients with Idiopathic Pulmonary Fibrosis (IPF).
19. 1305-0014: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF).
20. 1305-0023: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
21. GB44496: A two-cohort, phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of vixarelimab compared with placebo in patients with Idiopathic pulmonary fibrosis and in patients with systemic sclerosis associated interstitial lung disease.
22. GB44332 ARNISA: A Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of astegolimab in patients with chronic obstructive pulmonary disease.
23. 1305-0031: An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
24. 218224: A Phase 2/3, randomized, double-blind , placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)
25. PLN-74809-IPF-206: A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

26. OATD-01-C-03: A randomized, double-blind, dose-ranging, placebo-controlled, multicenter study to assess the efficacy and safety of a 12-week administration of OATD-01, an oral inhibitor of chitinase-1 (CHIT1), for the treatment of active pulmonary sarcoidosis.
27. IM0271015: A Multicenter, Randomized, double-blind, dose-ranging, placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
28. 1462-0004: A randomized, double-blind, dose-ranging, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF)
29. 1490-0004: A Phase IIa/IIb, randomized, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
30. VP-C21-011: A randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multicenter trial evaluating the efficacy and safety of 2 doses of budesonide over 52 weeks in people with idiopathic pulmonary fibrosis.
31. 10961: Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
32. 223529: The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub-study.

Achievement of the ILD Team, University of Crete:

1. Short term research fellowship, European Respiratory Society (2008) to George Margaritopoulos Interstitial Lung Disease Unit, Royal Brompton Hospital
2. Short term research fellowship, European Respiratory Society to Katerina Samara 2010
3. Long term research fellowship (12 months), European Respiratory Society (2010) to George Margaritopoulos, Interstitial Lung Disease Unit, Royal Brompton Hospital,
4. ERS Lung Science Congress Bursary 2010 to Konstantinos Karagiannis
5. ERS Travel Award, 2009 to Ismini Lasithiotaki, ERS Annual Congress, Vienna
6. ERS Travel Award, 2009 to A. Proklou, ERS Annual Congress, Vienna
7. ERS Lung Science Congress Bursary 2009 to F. Economidou
8. Long term research fellowship (12 months), European Respiratory Society (2012) to Konstantinos Karagiannis, Interstitial Lung Disease Unit, Royal Brompton Hospital, London
9. Short term research fellowship, European Respiratory Society (2015) to Athanasia Proklou Interstitial Lung Disease Unit, Royal Brompton Hospital
10. ERS Lung Science Congress Bursary 2018 to Eliza Tsitoura
11. ERS Lung Science Congress Bursary 2019 to Athina Trachalaki
12. Short Term ERS fellowship 2020 to Athina Trachalaki
13. Long Term ERS Research fellowship (12 months) 2021 to Eirini Vasarmidi

Representative Publications in peer reviewed Journals:

1. Otaola M, Vasarmidi E, Ottaviani S, Gutierrez M, Dalpiaz MS, Gaser A, Juge PA, Bertolazzi C, Avgoustidis N, Skiadas C, Della Maggiore M, Orausclio P, Quintana-Rodriguez A, Debray MP, Cepas BP, Schneeberger E, Sidiropoulos P, Schenone NL, Rosemffet M, Marciano S, **Antoniou K**. Performance of Lung Ultrasound as a Screening Tool for Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicenter Study. *Chest*. 2024 Dec 13;S0012-3692(24)05622-8.
2. Guiot J, Henket M, Gester F, André B, Ernst B, Frix AN, Smeets D, Van Eyndhoven S, **Antoniou K**, et al. Automated AI-based image analysis for quantification and prediction of interstitial lung disease in systemic sclerosis patients. *Respir Res*. 2025 Jan 24;26(1):39.
3. Wells AU, Jacob J, Sverzellati N, Cross G, Barnett J, De Lauretis A, **Antoniou K**, Weycker D, Atwood M, Kirchgaessler KU, Cottin V. A formula for predicting emphysema extent in combined idiopathic pulmonary fibrosis and emphysema. *Respir Res*. 2024 Jan 18;25(1):33.
4. **Antoniou KM**, et al. European Respiratory Society statement on long COVID follow-up. *Eur Respir J*. 2022 Aug 4;60(2):2102174.
5. Borie R, Kannengiesser C, **Antoniou K**, et al. European Respiratory Society statement on familial pulmonary fibrosis.

- EurRespir J. 2023 Mar 16;61(3):2201383.
6. Cottin V, Selman M, Inoue Y, Wong AW, Corte TJ, Flaherty KR, Han MK, Jacob J, Johannson KA, Kitaichi M, Lee JS, Agusti A, **Antoniou KM**, et al. Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. *Am J Respir Crit Care Med*. 2022 Aug 15;206(4):e7-e41.
 7. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, **Antoniou KM**, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2022 May 1;205(9):e18-e47.
 8. Trachalaki A, Tsitoura E, Mastrodimou S, Invernizzi R, Vasarmidi E, Bibaki E, Tzanakis N, Molyneaux PL, Maher TM, **Antoniou K**. Enhanced IL-1 β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis. *Front Immunol*. 2021;12:661811.
 9. Hunninghake GM, Goldin JG, Kadoch MA, Kropski JA, Rosas IO, Wells AU, Yadav R, Lazarus HM, Abtin FG, Corte TJ, de Andrade JA, Johannson KA, Kolb MR, Lynch DA, Oldham JM, Spagnolo P, Strek ME, Tomassetti S, Washko GR, White ES; ILA Study Group. Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative. *Chest*. 2021:S0012-3692(21)01263-0.
 10. Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, Rottoli P, Nunes H, Lower EE, Judson MA, Israel-Biet D, Grutters JC, Drent M, Culver DA, Bonella F, **Antoniou K**, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *EurRespir J*. 2021:2004079.
 11. Karampitsakos T, Torrisi S, **Antoniou K**, Manali E, Korbila I, Papaioannou O, et al. Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis. *Respir Res*. 2021;22(1):140Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, **Antoniou KM**, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.*EurRespir J*. 2021;57(4):2100048.
 12. Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, **Antoniou KM**, et al. Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2019;200(9):1146-53.
 13. Tsitoura E, Vasarmidi E, Bibaki E, Trachalaki A, Koutoulaki C, Papastratigakis G, Chalepakakis G, Tzanakis N, **Antoniou KM**. Accumulation of damaged mitochondria in alveolar macrophages with reduced OXPHOS related gene expression in IPF. *Respir Res*. 2019;20(1):264.
 14. Tzouveleakis A, Tzilas V, **Antoniou KM**, Bouros D. Human pentraxin 2 protein treatment for IPF. *Lancet Respir Med*. 2019;7(8):640-1.
 15. Alfaro TM, Moor CC, Alfieri V, Jeny F, Kreuter M, Wijsenbeek MS, Renzoni EA, Bargagli E, Nunes H, Spagnolo P, Bonella F, Molina-Molina M, **Antoniou K**, Poletti V. Research highlights from the 2018 ERS International Congress: interstitial lung diseases. *ERJ Open Res*. 2019;5(1).
 16. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group; IPF Consensus Working Group: Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name? *EurRespir J*. 2019;53(2).
 17. **Antoniou K**, Trachalaki A, Bibaki E, Poletti V. Assembly 12: interstitial lung diseases. *Breathe (Sheff)*. 2018;14(4):345-6.
 18. Margaritopoulos GA, Trachalaki A, Wells AU, Vasarmidi E, Bibaki E, Papastratigakis G, Detorakis S, Tzanakis N, **Antoniou KM**. Pirfenidone improves survival in IPF: results from a real-life study. *BMC Pulm Med*. 2018;18(1):177.
 19. Lasithiotaki I, Tsitoura E, Samara KD, Trachalaki A, Charalambous I, Tzanakis N, **Antoniou KM**. NLRP3/Caspase-1 inflammasome activation is decreased in alveolar macrophages in patients with lung cancer. *PLoS One*. 2018;13(10):e0205242.
 20. Bibaki E, Tsitoura E, Vasarmidi E, Margaritopoulos G, Trachalaki A, Koutoulaki C, Georgopoulou T, Spandidos DA, Tzanakis N, **Antoniou KM**. miR-185 and miR-29a are similarly expressed in the bronchoalveolar lavage cells in IPF and lung cancer but common targets DNMT1 and COL1A1 show disease specific patterns. *Mol Med Rep*. 2018;17(5):7105-12.
 21. Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, **Antoniou K**, et al. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. *N Engl J Med*. 2018;379(23):2209-19.

22. Bouros D, Daniil Z, Papakosta D, **Antoniou KM**, Markopoulou K, Kolilekas L, et al. Design, Rationale, Methodology, and Aims of a Greek Prospective Idiopathic Pulmonary Fibrosis Registry: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF). *Respiration*. 2018;96(1):41-7.
23. Samara KD, Trachalaki A, Tsitoura E, Koutsopoulos AV, Lagoudaki ED, Lasithiotaki I, Margaritopoulos G, Pantelidis P, Bibaki E, Siafakas NM, Tzanakis N, Wells AU, **Antoniou KM**. Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis. *Respir Res*. 2017;18(1):218.
24. Molina-Molina M, Agusti A, Crestani B, Schwartz DA, Königshoff M, Chambers RC, Maher TM, Faner R, Mora AL, Rojas M, **Antoniou KM**, Sellares J. Towards a global initiative for fibrosis treatment (GIFT). *ERJ Open Res*. 2017;3(4).
25. Vassalou EE, Raissaki M, Magkanas E, **Antoniou KM**, Karantanis AH. Lung Ultrasonography in Patients With Idiopathic Pulmonary Fibrosis: Evaluation of a Simplified Protocol With High-Resolution Computed Tomographic Correlation. *J Ultrasound Med*. 2018;37(3):689-696.
26. Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, **Antoniou KM** et al. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *EurRespir J*. 2017;50(2).
27. Johansson KA, Strambu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, et al. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? *Lancet Respir Med*. 2017;5(7):591-8.
28. **Antoniou KM**, Karagiannis K, Tsitoura E, Tzanakis N. Mesenchymal stem cell treatment for IPF-time for phase 2 trials? *Lancet Respir Med*. 2017;5(6):472-3.
29. Cottin V, Hansell DM, Sverzellati N, Weycker D, **Antoniou KM**, Atwood M, et al. Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2017;196(9):1162-1171.
30. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, **Antoniou KM** et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *Am J Respir Crit Care Med*. 2016;194(3):265-75.
31. **Antoniou KM**, Margaritopoulos GA, Goh NS, Karagiannis K, Desai SR, Nicholson AG, et al. Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension. *Arthritis Rheumatol*. 2016;68(4):1004-12.
32. Lasithiotaki I, Giannarakis I, Tsitoura E, Samara KD, Margaritopoulos GA, Choulaki C, Vasarmidi E, Tzanakis N, Voloudaki A, Sidiropoulos P, Siafakas NM, **Antoniou KM**. NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung. *EurRespir J*. 2016;47(3):910-8.
33. Fischer A, **Antoniou KM**, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. *EurRespir J*. 2015;46(4):976-87.
34. Wuyts WA, **Antoniou KM**, Borensztajn K, Costabel U, Cottin V, Crestani B, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? *Lancet Respir Med*. 2014;2(11):933-42.
35. Walsh SL, Wells AU, Sverzellati N, Keir GJ, Calandriello L, **Antoniou KM**, et al. An integrated clinicroadiological staging system for pulmonary sarcoidosis: a case-cohort study. *Lancet Respir Med*. 2014;2(2):123-30.
36. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, **Antoniou K**, et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax*. 2014;69(5):428-36.
37. **Antoniou KM**, Walsh SL, Hansell DM, Rubens MR, Marten K, Tennant R, et al. Smoking-related emphysema is associated with idiopathic pulmonary fibrosis and rheumatoid lung. *Respirology*. 2013;18(8):1191-6.
38. Marten K, Milne D, **Antoniou KM**, Nicholson AG, Tennant RC, Hansel TT, et al. Non-specific interstitial pneumonia in cigarette smokers: a CT study. *EurRadiol*. 2009;19(7):1679-85.
39. **Antoniou KM**, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. *EurRespir J*. 2009;33(4):882-96.
40. **Antoniou KM**, Wells AU. Scleroderma lung disease: evolving understanding in light of newer studies. *CurrOpinRheumatol*. 2008;20(6):686-91.
41. **Antoniou KM**, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. *Am J Respir Crit Care Med*. 2008;177(2):190-4.
42. Bouros D, **Antoniou KM**, Light RW. Intrapleural streptokinase for pleural infection. *BMJ*. 2006;332(7534):133-4.
43. **Antoniou KM**, Nicholson AG, Dimadi M, Malagari K, Latsi P, Rapti A, et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. *EurRespir J*. 2006;28(3):496-504.

